Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03765762 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Safety of GRF6019 Infusions in Subjects With Severe Alzheimer's Disease
A Phase 2 study, sponsored by Alkahest.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT03765762 is a Phase 2 study that has completed, run by Alkahest. The registered enrollment target is 26 participants.
The verdict
NCT03765762, a Phase 2 study, has completed, sponsored by Alkahest.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
This study will evaluate the safety, tolerability, and potential cognitive benefit of the experimental treatment GRF6019 in subjects with severe Alzheimer's disease.
Interventions
- OTHER Placebo
- DRUG GRF6019
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2019-01-15 |
| Est. Completion | 2019-12-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03765762
The ClinicalTrials.gov registry entry for NCT03765762 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alkahest, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03765762 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03765762 about?
NCT03765762 is a clinical study titled "A Study to Assess the Safety of GRF6019 Infusions in Subjects With Severe Alzheimer's Disease". This study will evaluate the safety, tolerability, and potential cognitive benefit of the experimental treatment GRF6019 in subjects with severe Alzheimer's disease.
What is the current status of trial NCT03765762?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2019-01-15. Estimated completion is 2019-12-17.
What interventions are being tested in trial NCT03765762?
The interventions under investigation include: Placebo (OTHER), GRF6019 (DRUG).
Who is sponsoring clinical trial NCT03765762?
This trial is sponsored by Alkahest, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.